Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Nathan S. Kline Institute for Psychiatric Research

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rfmh.org

Clinical Trials

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

Phase 2

Withdrawn

Conditions: Schizophrenic Disorders
Cognitive Function

Interventions: Dietary Supplement: Sodium Butyrate
Other: Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2016-08-15

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Registration Number: NCT02654405

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg,, New York, United States

D-serine and Cognitive Remediation in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: D-serine

First Posted Date: 2014-06-05

Last Posted Date: 2020-10-08

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 8

Registration Number: NCT02156908

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

Not Applicable

Completed

Conditions: Cognition
Cigarette Smoking
Schizophrenia

Interventions: Device: tDCS

First Posted Date: 2014-05-01

Last Posted Date: 2017-08-30

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 33

Registration Number: NCT02128919

Locations: 🇺🇸
Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Phase 2

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: placebo
Drug: D-serine
Behavioral: Sensory Based remediation paradigm

First Posted Date: 2011-11-18

Last Posted Date: 2012-10-25

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 16

Registration Number: NCT01474395

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States

Conversion to Antipsychotic Monotherapy

Not Applicable

Terminated

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Other: Conversion to Antipsychotic Monotherapy

First Posted Date: 2011-06-08

Last Posted Date: 2017-02-09

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 24

Registration Number: NCT01368458

Metformin for Weight Loss in Schizophrenia

Not Applicable

Terminated

Conditions: Schizophrenia
Obesity

Interventions: Drug: Metformin

First Posted Date: 2010-08-09

Last Posted Date: 2017-09-01

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 12

Registration Number: NCT01177709

Locations: 🇺🇸
Manhatan Psychiatric Center, New York, New York, United States

Clozapine and Olanzapine Treatment of Aggression

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: Clozapine
Drug: Haloperidol

First Posted Date: 2010-05-14

Last Posted Date: 2010-05-14

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 110

Registration Number: NCT01123408

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

Cognitive Skills Training Using Computer for Patients With Severe Mental Illness

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Behavioral: CRT and Social Cognition
Behavioral: Computerized Cognitive Skill Training

First Posted Date: 2009-12-21

Last Posted Date: 2017-07-21

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 448

Registration Number: NCT01036282

Locations: 🇺🇸
Manhattan Psychiatric Center, New York, New York, United States

D-serine for the Schizophrenia Prodrome

Phase 2

Completed

Conditions: Schizophrenia Prodrome

Interventions: Drug: D-serine
Other: Placebo

First Posted Date: 2009-01-22

Last Posted Date: 2017-08-14

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 44

Registration Number: NCT00826202

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Zucker Hillside Hospital, Glen Oaks, New York, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States

and more 1 locations

Biomarkers in Schizophrenia

Phase 2

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: D Serine
Drug: Placebo

First Posted Date: 2009-01-06

Last Posted Date: 2017-08-02

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 16

Registration Number: NCT00817336

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy